Autophagy in drug resistance of the multiple myeloma cell line RPMI8226 to doxorubicin

Yz, Pan; Wang, X; Bai, Hao; Wang, CB; Zhang, Q; R, Xi

doi:10.4238/2015.may.25.14

Cited by 16 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results are also obtained in a multiple myeloma cell line, Pan et al (37) reported that expression level of LC3-Ⅱ was higher in DOX-resistant RPMI8226/DOX cells than in DOXsensitive RPMI8226/S cells. Similarly, compared with K562 cells, there is an increased PI3K/AKT/mTOR signaling and enhanced autophagic activity in imatinibresistant human chronic myelogenous leukemia K562R cells (38).…”

Section: Discussionsupporting

confidence: 80%

Differences of basic and induced autophagic activity between K562 and K562/ADM cells

Wang

Chen

Zhang

et al. 2017

IRDR

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 80%

Differences of basic and induced autophagic activity between K562 and K562/ADM cells

Wang

Chen

Zhang

et al. 2017

IRDR

View full text Add to dashboard Cite

“…Resveratrol can enhance the chemotherapeutic potential of DOX by inducing apoptosis mediated through down regulation of autophagy in breast cancer cell lines (Rai et al, 2016). Additionally, HCQ or 3-MA can partially reverse the drug resistance of myeloma RPMI8226/DOX cells by inhibition of autophagy (Pan et al, 2015). Pirarubicin is widely used in clinical chemotherapy for bladder cancer.…”

Section: Conventional Cytotoxic Drugsmentioning

confidence: 99%

Combination of an Autophagy Inducer and an Autophagy Inhibitor: A Smarter Strategy Emerging in Cancer Therapy

Liu

Zhang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Autophagy is considered a cytoprotective function in cancer therapy under certain conditions and is a drug resistance mechanism that represents a clinical obstacle to successful cancer treatment and leads to poor prognosis in cancer patients. Because certain clinical drugs and agents in development have cytoprotective autophagy effects, targeting autophagic pathways has emerged as a potential smarter strategy for cancer therapy. Multiple preclinical and clinical studies have demonstrated that autophagy inhibition augments the efficacy of anticancer agents in various cancers. Autophagy inhibitors, such as chloroquine and hydroxychloroquine, have already been clinically approved, promoting drug combination treatment by targeting autophagic pathways as a means of discovering and developing more novel and more effective cancer therapeutic approaches. We summarize current studies that focus on the antitumor efficiency of agents that induce cytoprotective autophagy combined with autophagy inhibitors. Furthermore, we discuss the challenge and development of targeting cytoprotective autophagy as a cancer therapeutic approach in clinical application. Thus, we need to facilitate the exploitation of appropriate autophagy inhibitors and coadministration delivery system to cooperate with anticancer drugs. This review aims to note optimal combination strategies by modulating autophagy for therapeutic advantage to overcome drug resistance and enhance the effect of antitumor therapies on cancer patients.

show abstract

“…The double sided functions of autophagy implicate its paradoxical roles in anticancer treatments, increasing or diminishing their anticancer activity. However, an increasing amount of evidence suggests that autophagy׳s pro-survival function plays a significant role in chemoresistance in a many different cancer types33, 34, 35, 36, 37, 38.…”

Section: Mechanisms Of Multidrug Resistancementioning

confidence: 99%

Regulation of multidrug resistance by microRNAs in anti-cancer therapy

An¹,

Sarmiento

Tan

et al. 2017

Acta Pharmaceutica Sinica B

165

132

View full text Add to dashboard Cite

Multidrug resistance (MDR) remains a major clinical obstacle to successful cancer treatment. Although diverse mechanisms of MDR have been well elucidated, such as dysregulation of drugs transporters, defects of apoptosis and autophagy machinery, alterations of drug metabolism and drug targets, disrupti on of redox homeostasis, the exact mechanisms of MDR in a specific cancer patient and the cross-talk among these different mechanisms and how they are regulated are poorly understood. MicroRNAs (miRNAs) are a new class of small noncoding RNAs that could control the global activity of the cell by post-transcriptionally regulating a large variety of target genes and proteins expression. Accumulating evidence shows that miRNAs play a key regulatory role in MDR through modulating various drug resistant mechanisms mentioned above, thereby holding much promise for developing novel and more effective individualized therapies for cancer treatment. This review summarizes the various MDR mechanisms and mainly focuses on the role of miRNAs in regulating MDR in cancer treatment.

show abstract

Autophagy in drug resistance of the multiple myeloma cell line RPMI8226 to doxorubicin

Cited by 16 publications

References 11 publications

Differences of basic and induced autophagic activity between K562 and K562/ADM cells

Differences of basic and induced autophagic activity between K562 and K562/ADM cells

Combination of an Autophagy Inducer and an Autophagy Inhibitor: A Smarter Strategy Emerging in Cancer Therapy

Regulation of multidrug resistance by microRNAs in anti-cancer therapy

Contact Info

Product

Resources

About